Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

Background: Nusinersen was the first approved disease-modifying therapy for all 5q-spinal muscular atrophy (SMA) patients regardless of age or disease severity. Its efficacy in adults has recently been demonstrated in a large cohort by motor outcome measures, which were only partially suitable to de...

Full description

Bibliographic Details
Main Authors: Alma Osmanovic, Gresa Ranxha, Mareike Kumpe, Claudia D. Wurster, Benjamin Stolte, Isabell Cordts, René Günther, Maren Freigang, Lars H. Müschen, Camilla Binz, Andreas Hermann, Marcus Deschauer, Paul Lingor, Albert C. Ludolph, Tim Hagenacker, Olivia Schreiber-Katz, Susanne Petri
Format: Article
Language:English
Published: SAGE Publishing 2021-03-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756286421998902

Internet

https://doi.org/10.1177/1756286421998902

Similar Items